Melanocortin ligands: 30 years of structure–activity relationship (SAR) studies

The challenge of peptide and peptidomimetic research is the development of methods and techniques to improve the biological properties of native peptides and to convert peptide ligands into non‐peptide compounds. Improved biological properties of peptides includes enhancement of stability, potency, and receptor selectivity, for both in vivo and in vitro applications. The design of a ligand with specific activity and desired biological properties is a complex task, and, to accomplish this objective, knowledge about putative interactions between a ligand and the corresponding receptor will be valuable. This includes interactions for both the binding and signal transduction processes. Structure–activity relationship (SAR) studies involve systematic modification of a lead peptide and are designed to provide insight into potential interactions involved in the formation of the ligand–receptor complex. It is desirable to have knowledge about both favorable and unfavorable processes that may occur in putative ligand–receptor interactions that result in either receptor stimulation or inhibition. Herein, we discuss various SAR studies that have involved melanocortin peptides over three decades and the information these studies have provided to the melanocortin field. © 2004 Wiley Periodicals, Inc. Med Res Rev, 24, No. 3, 325–356, 2004

[1]  P. Prusis,et al.  Selectivity of Cyclic [d-Nal7] and [d-Phe7] Substituted MSH Analogues for the Melanocortin Receptor Subtypes , 1997, Peptides.

[2]  V. Hruby,et al.  Cyclic lactam analogues of Ac-[Nle4]alpha-MSH4-11-NH2. , 1988, Biochemistry.

[3]  G. Barsh,et al.  Effects of recombinant agouti-signaling protein on melanocortin action. , 1997, Molecular endocrinology.

[4]  R. Cone,et al.  A Unique Metalolic Sysdrone Causes Obesity in the Melanocortin-3 Receptor-Deficient Mouse. , 2000, Endocrinology.

[5]  P. Grieco,et al.  Synthesis and biological evaluation on hMC3, hMC4 and hMC5 receptors of gamma-MSH analogs substituted with L-alanine. , 2002, The journal of peptide research : official journal of the American Peptide Society.

[6]  V. Hruby,et al.  Chapter 30. Recent Progress in the Rational Design of Peptide Hormones and Neurotransmitters , 1984 .

[7]  V. Hruby,et al.  Structure‐Activity Relationships of [Nle4, D‐Phe7]α‐MSH , 1993 .

[8]  J. Deshusses,et al.  Synthesis and characterization of an acylated di-peptide (Myr-Trp-Leu) with modified transmucosal transport properties. , 1999, European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V.

[9]  Y. Lee,et al.  A novel melanocortin 3 receptor gene (MC3R) mutation associated with severe obesity. , 2002, The Journal of clinical endocrinology and metabolism.

[10]  I. Jackson,et al.  The Asp84Glu variant of the melanocortin 1 receptor (MC1R) is associated with melanoma. , 1996, Human molecular genetics.

[11]  G. Barsh,et al.  Genetic studies of the mouse mutations mahogany and mahoganoid. , 1997, Genetics.

[12]  H. Schiöth,et al.  Evidence for expression of melanocortin-1 receptor in human sebocytes in vitro and in situ. , 2002, The Journal of investigative dermatology.

[13]  P. Bork,et al.  The mahogany protein is a receptor involved in suppression of obesity , 1999, Nature.

[14]  R. Cone The Melanocortin Receptors , 2000, The Receptors.

[15]  R. Cone Melanocortin Receptors, The , 2000 .

[16]  V J Hruby,et al.  Design of peptides, proteins, and peptidomimetics in chi space. , 1997, Biopolymers.

[17]  J. Baik,et al.  Type I beta-turn conformation is important for biological activity of the melanocyte-stimulating hormone analogues. , 1999, European journal of biochemistry.

[18]  V. Hruby,et al.  Conformational and topographical considerations in the design of biologically active peptides , 1993, Biopolymers.

[19]  R. Seeley,et al.  A Novel Selective Melanocortin-4 Receptor Agonist Reduces Food Intake in Rats and Mice without Producing Aversive Consequences , 2000, The Journal of Neuroscience.

[20]  S. Watson,et al.  Molecular cloning, expression, and gene localization of a fourth melanocortin receptor. , 1993, The Journal of biological chemistry.

[21]  J. Weiel,et al.  Agouti structure and function: characterization of a potent alpha-melanocyte stimulating hormone receptor antagonist. , 1995, Biochemistry.

[22]  M. Bednarek,et al.  Analogs of MTII, lactam derivatives of alpha-melanotropin, modified at the N-terminus, and their selectivity at human melanocortin receptors 3, 4, and 5. , 1999, Biochemical and biophysical research communications.

[23]  H. Schiöth The physiological role of melanocortin receptors. , 2001, Vitamins and hormones.

[24]  A. Turnbull,et al.  Pro-opiomelanocortin processing in the hypothalamus: impact on melanocortin signalling and obesity. , 2002, The Journal of endocrinology.

[25]  Ronald W. Davis,et al.  The mouse mahogany locus encodes a transmembrane form of human attractin , 1999, Nature.

[26]  T. Luger,et al.  The Role of Melanocortins in Skin Homeostasis , 2001, Hormone Research in Paediatrics.

[27]  K. Georgeson,et al.  Molecular Determinants of Human Melanocortin-4 Receptor Responsible for Antagonist SHU9119 Selective Activity* , 2002, The Journal of Biological Chemistry.

[28]  V. Hruby,et al.  [half-Cys4,half-Cys10]-alpha-Melanocyte-stimulating hormone: a cyclic alpha-melanotropin exhibiting superagonist biological activity. , 1982, Proceedings of the National Academy of Sciences of the United States of America.

[29]  V J Hruby,et al.  Discovery of prototype peptidomimetic agonists at the human melanocortin receptors MC1R and MC4R. , 1997, Journal of medicinal chemistry.

[30]  T. Fitzpatrick,et al.  In vitro bioassay for the melanocyte stimulating hormone. , 1954, Endocrinology.

[31]  J. Tokarski,et al.  Discovery of tyrosine-based potent and selective melanocortin-1 receptor small-molecule agonists with anti-inflammatory properties. , 2003, Journal of medicinal chemistry.

[32]  M. Bednarek,et al.  Selective, high affinity peptide antagonists of alpha-melanotropin action at human melanocortin receptor 4: their synthesis and biological evaluation in vitro. , 2001, Journal of medicinal chemistry.

[33]  G. Barsh,et al.  Antagonism of central melanocortin receptors in vitro and in vivo by agouti-related protein. , 1997, Science.

[34]  C. Haskell-Luevano,et al.  Urea small molecule agonists on mouse melanocortin receptors. , 2003, Bioorganic & medicinal chemistry letters.

[35]  M. Mortrud,et al.  Identification of a receptor for gamma melanotropin and other proopiomelanocortin peptides in the hypothalamus and limbic system. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[36]  Reductive amination products containing naphthalene and indole moieties bind to melanocortin receptors. , 2002, Bioorganic & medicinal chemistry letters.

[37]  Victor J. Hruby,et al.  Role of melanocortinergic neurons in feeding and the agouti obesity syndrome , 1997, Nature.

[38]  J. Cheetham,et al.  Structure-activity relationship of (1-aryl-2-piperazinylethyl)piperazines: antagonists for the AGRP/melanocortin receptor binding. , 2003, Journal of medicinal chemistry.

[39]  Xin-jie Chu,et al.  Structure-activity relationship of linear peptide Bu-His-DPhe-Arg-Trp-Gly-NH(2) at the human melanocortin-1 and -4 receptors: histidine substitution. , 2002, Bioorganic & medicinal chemistry letters.

[40]  L. Lundin,et al.  Val92Met variant of the melanocyte stimulating hormone receptor gene , 1996, Nature Genetics.

[41]  J. Wikberg,et al.  Loss of function mutations of the human melanocortin 1 receptor are common and are associated with red hair. , 1999, Biochemical and biophysical research communications.

[42]  V. Hruby,et al.  Design, Synthesis, and Conformation of Superpotent and Prolonged Acting Melanotropins a , 1993, Annals of the New York Academy of Sciences.

[43]  V. Hruby,et al.  beta-Methylation of the Phe7 and Trp9 melanotropin side chain pharmacophores affects ligand-receptor interactions and prolonged biological activity. , 1997, Journal of medicinal chemistry.

[44]  D. I. Våge,et al.  The melanocortin receptors: agonists, antagonists, and the hormonal control of pigmentation. , 1996, Recent progress in hormone research.

[45]  C. Haskell-Luevano,et al.  Structure–activity relationships of the melanocortin tetrapeptide Ac-His-DPhe-Arg-Trp-NH2 at the mouse melanocortin receptors Part 3: modifications at the Arg position , 2003, Peptides.

[46]  W. Sterry,et al.  New treatment modalities for basal cell carcinoma. , 2002, Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer.

[47]  M. Mihm,et al.  ACTH receptor, CYP11A1, CYP17 and CYP21A2 genes are expressed in skin. , 1996, The Journal of clinical endocrinology and metabolism.

[48]  R. Cone,et al.  Structure activity studies of the melanocortin antagonist SHU9119 modified at the 6, 7, 8, and 9 positions☆ , 2000, Peptides.

[49]  C. Humblet,et al.  Three-dimensional molecular models of the hMC1R melanocortin receptor: complexes with melanotropin peptide agonists. , 1996, Drug design and discovery.

[50]  V. Hruby,et al.  Topographically designed analogues of [D-Pen,D-Pen5]enkephalin. , 1991, Journal of medicinal chemistry.

[51]  C. Beglinger,et al.  A combinatorial peptoid library for the identification of novel MSH and GRP/bombesin receptor ligands. , 1999, Journal of receptor and signal transduction research.

[52]  A. Lerner,et al.  On the movement of pigment granules in frog melanocytes. , 1960, Endocrinology.

[53]  J. M. Lipton,et al.  The Neuroimmunomodulatory Peptide α‐MSH , 2000 .

[54]  I. Gantz,et al.  Molecular Basis for the Interaction of [Nle4,d-Phe7]Melanocyte Stimulating Hormone with the Human Melanocortin-1 Receptor (Melanocyte α-MSH Receptor)* , 1997, The Journal of Biological Chemistry.

[55]  C. Haskell-Luevano,et al.  Characterization of melanocortin NDP-MSH agonist peptide fragments at the mouse central and peripheral melanocortin receptors. , 2001, Journal of medicinal chemistry.

[56]  V. Slepnev,et al.  Fatty acid acylated peroxidase as a model for the study of interactions of hydrophobically-modified proteins with mammalian cells. , 1995, Bioconjugate chemistry.

[57]  Yue Feng,et al.  Inactivation of the mouse melanocortin-3 receptor results in increased fat mass and reduced lean body mass , 2000, Nature Genetics.

[58]  Z. Abdel‐Malek Melanocortin receptors: their functions and regulation by physiological agonists and antagonists , 2001, Cellular and Molecular Life Sciences CMLS.

[59]  R. Cone,et al.  Characterization of melanocortin receptor subtype expression in murine adipose tissues and in the 3T3-L1 cell line. , 1996, Endocrinology.

[60]  C. Grunfeld,et al.  Characterization of adrenocorticotropin receptors that appear when 3T3-L1 cells differentiate into adipocytes. , 1985, Endocrinology.

[61]  V. Hruby,et al.  Quantitative determination of amino acid racemization in heat--alkali-treated melanotropins: implications for peptide hormone structure--function studies. , 1981, Analytical biochemistry.

[62]  J. Shutter,et al.  Hypothalamic expression of ART, a novel gene related to agouti, is up-regulated in obese and diabetic mutant mice. , 1997, Genes & development.

[63]  V. Hruby,et al.  The Molecular Pharmacology of Alpha-Melanocyte Stimulating Hormone: Structure-Activity Relationships for Melanotropins at Melanocortin Receptors , 2000 .

[64]  V. Hruby,et al.  Enzymological studies of melanotropins. , 1984, Comparative biochemistry and physiology. B, Comparative biochemistry.

[65]  M. Meldal,et al.  A solid-phase approach to mouse melanocortin receptor agonists derived from a novel thioether cyclized peptidomimetic scaffold. , 2002, Journal of the American Chemical Society.

[66]  R. Woychik,et al.  Molecular characterization of the mouse agouti locus , 1992, Cell.

[67]  V. Hruby,et al.  Emerging approaches in the molecular design of receptor-selective peptide ligands: conformational, topographical and dynamic considerations. , 1990, The Biochemical journal.

[68]  V. Hruby,et al.  α-Melanocyte stimulating hormone message and inhibitory sequences: Comparative structure-activity studies on melanocytes , 1990, Peptides.

[69]  S. O’Rahilly,et al.  A frameshift mutation in MC4R associated with dominantly inherited human obesity , 1998, Nature Genetics.

[70]  Ximena Opitz-Araya,et al.  Exocrine Gland Dysfunction in MC5-R-Deficient Mice: Evidence for Coordinated Regulation of Exocrine Gland Function by Melanocortin Peptides , 1997, Cell.

[71]  J. Hebebrand,et al.  Candidate gene polymorphisms in eating disorders. , 2000, European journal of pharmacology.

[72]  G. Landis,et al.  Ring substituted and other conformationally constrained tyrosine analogues of [D-Pen2,D-Pen5]enkephalin with delta opioid receptor selectivity. , 1992, Journal of medicinal chemistry.

[73]  N. R. Douglas,et al.  Peptoid mimics of agouti related protein. , 2003, Bioorganic & medicinal chemistry letters.

[74]  L. Gantert,et al.  Activation of melanocortin MC(4) receptors increases erectile activity in rats ex copula. , 2002, European journal of pharmacology.

[75]  V. Hruby,et al.  4-Norleucine, 7-D-phenylalanine-alpha-melanocyte-stimulating hormone: a highly potent alpha-melanotropin with ultralong biological activity. , 1980, Proceedings of the National Academy of Sciences of the United States of America.

[76]  R. Cone,et al.  Targeted Disruption of the Melanocortin-4 Receptor Results in Obesity in Mice , 1997, Cell.

[77]  V. Hruby,et al.  Characterizations of the unusual dissociation properties of melanotropin peptides from the melanocortin receptor, hMC1R. , 1996, Journal of medicinal chemistry.

[78]  P. Prusis,et al.  Long term orexigenic effect of a novel melanocortin 4 receptor selective antagonist , 1999, British journal of pharmacology.

[79]  M. Bednarek,et al.  1H‐NMR studies on a potent and selective antagonist at human melanocortin receptor 4 (hMC‐4R) , 2003, Biopolymers.

[80]  V. Hruby,et al.  Biological activities of melanotropic peptide fatty acid conjugates. , 1991, Pigment cell research.

[81]  V. Hruby,et al.  Structure and dynamics of α-MSH using DRISM integral equation theory and stochastic dynamics , 1999 .

[82]  T K Sawyer,et al.  Alpha-melanotropin: the minimal active sequence in the lizard skin bioassay. , 1989, General and comparative endocrinology.

[83]  T. Luger,et al.  The Role of α‐MSH as a Modulator of Cutaneous Inflammation , 2000 .

[84]  B. Pettitt,et al.  Modeling of alpha-MSH conformations with implicit solvent. , 1999, The journal of peptide research : official journal of the American Peptide Society.

[85]  R. Cone,et al.  Compounds that activate the mouse melanocortin-1 receptor identified by screening a small molecule library based upon the beta-turn. , 1999, Journal of medicinal chemistry.

[86]  H. Bundgaard,et al.  Prodrugs of Peptides. 6. Bioreversible Derivatives of Thyrotropin-Releasing Hormone (TRH) with Increased Lipophilicity and Resistance to Cleavage by the TRH-Specific Serum Enzyme , 1990, Pharmaceutical Research.

[87]  Richard P. Woychik,et al.  Agouti protein is an antagonist of the melanocyte-stimulating-hormone receptor , 1994, Nature.

[88]  S. Lande Racemization of a-melanotropin , 1971 .

[89]  H. Bundgaard,et al.  Prodrugs of peptides. IV: Bioreversible derivatization of the pyroglutamyl group by N-acylation and N-aminomethylation to effect protection against pyroglutamyl aminopeptidase. , 1989, Journal of pharmaceutical sciences.

[90]  V. Hruby,et al.  Synthesis and biological activities of fatty acid conjugates of a cyclic lactam alpha-melanotropin. , 1992, Journal of medicinal chemistry.

[91]  M. Mortrud,et al.  The cloning of a family of genes that encode the melanocortin receptors. , 1992, Science.

[92]  Hongmao Sun,et al.  Highly Selective Cyclic Peptides for Human Melanocortin-4 Receptor (MC-4 R): Design, Synthesis, Bioactive Conformation, and Pharmacological Evaluation as an Anti-Obesity Agent , 2001 .

[93]  W. Chung,et al.  The mouse mahoganoid coat color mutation disrupts a novel C3HC4 RING domain protein. , 2002, The Journal of clinical investigation.

[94]  D. Cross-Doersen,et al.  Synthesis of 2,4,5-trisubstituted tetrahydropyrans as peptidomimetic scaffolds for melanocortin receptor ligands. , 2003, Organic letters.

[95]  M. Linder,et al.  Signalling functions of protein palmitoylation. , 1998, Biochimica et biophysica acta.

[96]  M. Lerner,et al.  Discovery and structure-function analysis of alpha-melanocyte-stimulating hormone antagonists. , 1994, The Journal of biological chemistry.

[97]  Victor J. Hruby,et al.  D-amino acid scan of γ-melanocyte-stimulating hormone : Importance of Trp8 on human MC3 receptor selectivity , 2000 .

[98]  P. Grieco,et al.  Design and synthesis of highly potent and selective melanotropin analogues of SHU9119 modified at position 6. , 2002, Biochemical and biophysical research communications.

[99]  D. Johnston,et al.  Design and pharmacology of N-[(3R)-1,2,3,4-tetrahydroisoquinolinium- 3-ylcarbonyl]-(1R)-1-(4-chlorobenzyl)- 2-[4-cyclohexyl-4-(1H-1,2,4-triazol- 1-ylmethyl)piperidin-1-yl]-2-oxoethylamine (1), a potent, selective, melanocortin subtype-4 receptor agonist. , 2002, Journal of medicinal chemistry.

[100]  M. Bednarek,et al.  Structure-function studies on the cyclic peptide MT-II, lactam derivative of α-melanotropin☆ ☆ Throughout this report, the numbering of the amino acid residues in α-MSH has been retained for all linear and cyclic peptides. , 1999, Peptides.

[101]  H. Schiöth,et al.  Novel selective melanocortin 4 receptor antagonist induces food intake after peripheral administration. , 2003, Biochemical and biophysical research communications.

[102]  D. Sargent,et al.  Membrane lipid phase as catalyst for peptide-receptor interactions. , 1986, Proceedings of the National Academy of Sciences of the United States of America.

[103]  Robert Fredriksson,et al.  One melanocortin 4 and two melanocortin 5 receptors from zebrafish show remarkable conservation in structure and pharmacology , 2002, Journal of neurochemistry.

[104]  Paolo Grieco,et al.  Structure-activity studies of the melanocortin peptides: discovery of potent and selective affinity antagonists for the hMC3 and hMC4 receptors. , 2002, Journal of medicinal chemistry.

[105]  V. Hruby,et al.  Design, Synthesis, Biology, and Conformations of Bicyclic α-Melanotropin Analogues , 1995 .

[106]  R. Horváth,et al.  Newly discovered stereochemical requirements in the side-chain conformation of delta opioid agonists for recognizing opioid delta receptors. , 1994, Journal of medicinal chemistry.

[107]  V. Hruby,et al.  Synthesis and biological actions of highly potent and prolonged acting biotin-labeled melanotropins. , 1984, Journal of medicinal chemistry.

[108]  T. Luger,et al.  Expression of melanocortin‐1 receptor in normal, malformed and neoplastic skin glands and hair follicles , 2002, Experimental dermatology.

[109]  K. Kopple,et al.  Reverse Turns in Peptides and Protein , 1980 .

[110]  T. H. Lee,et al.  On the mechanism of sodium hydroxide modification of alpha-melanocyte-stimulating hormone. , 1963, The Journal of biological chemistry.

[111]  V. Hruby,et al.  Truncation studies of α-melanotropin peptides identify tripeptide analogues exhibiting prolonged agonist bioactivity , 1996, Peptides.

[112]  J. Bolognia,et al.  The melanocortin-1 receptor: red hair and beyond. , 2001, Archives of dermatology.

[113]  S. McGurk,et al.  Ligand-dependent activation of the melanocortin 5 receptor: cAMP production and ryanodine receptor-dependent elevations of [Ca(2+)](I). , 2002, Biochemical and Biophysical Research Communications - BBRC.

[114]  T. Glover,et al.  Localization of the genes encoding the melanocortin-2 (adrenocorticotropic hormone) and melanocortin-3 receptors to chromosomes 18p11.2 and 20q13.2-q13.3 by fluorescence in situ hybridization. , 1993, Genomics.

[115]  M. Mortrud,et al.  Localization of the melanocortin-4 receptor (MC4-R) in neuroendocrine and autonomic control circuits in the brain. , 1994, Molecular endocrinology.

[116]  J. Wikberg,et al.  Molecular cloning of a novel human melanocortin receptor. , 1993, Biochemical and biophysical research communications.

[117]  E. Coutinho,et al.  Comparative conformational studies on cyclic hexapeptides corresponding to message sequence His-Phe-Arg-Trp of alpha-melanotropin by NMR. , 2009, The journal of peptide research : official journal of the American Peptide Society.

[118]  F. Moore,et al.  α-Melanocyte-stimulating hormone protects against mesenteric ischemia-reperfusion injury , 2002 .

[119]  H. Süli‐Vargha,et al.  Synthesis and biological activity of cyclic melanotropin peptides , 1991 .

[120]  Huiling He,et al.  Gene expression analysis of glucocorticoid-induced apoptosis by a gene microarray technique , 2001, Nature Genetics.

[121]  S. Watson,et al.  Molecular cloning of a novel melanocortin receptor. , 1993, The Journal of biological chemistry.

[122]  V J Hruby,et al.  alpha-Melanotropin: the minimal active sequence in the frog skin bioassay. , 1987, Journal of medicinal chemistry.

[123]  V. Hruby,et al.  Synthesis and Biological Evaluation of the Superagonist [Nα-Chlorotriazinylaminofluorescein-Ser1, Nle4, D-Phe7]-α-MSH , 1985 .

[124]  A. Lomize,et al.  Development of a model for the delta opioid receptor pharmacophore. 1. Conformationally restricted Tyr1 replacements in the cyclic delta receptor selective tetrapeptide Tyr-c[D-Cys-Phe-D-Pen]OH (JOM-13). , 1994, Journal of medicinal chemistry.

[125]  P. Prusis,et al.  Discovery of novel melanocortin4 receptor selective MSH analogues , 1998, British journal of pharmacology.

[126]  D. H. Lee,et al.  2,3-Diaryl-5-anilino[1,2,4]thiadiazoles as melanocortin MC4 receptor agonists and their effects on feeding behavior in rats. , 2003, Bioorganic & medicinal chemistry.

[127]  V. Hruby,et al.  Conformational and dynamic considerations in peptide structure-function studies , 1982, Peptides.

[128]  R. Nagaraj,et al.  Interaction of a hydrophobic model peptide and its fatty acid derivative with lipid vesicles , 1988, FEBS letters.

[129]  M. Tota,et al.  ART (protein product of agouti-related transcript) as an antagonist of MC-3 and MC-4 receptors. , 1997, Biochemical and biophysical research communications.

[130]  V. Hruby,et al.  Topographical modification of melanotropin peptide analogues with beta-methyltryptophan isomers at position 9 leads to differential potencies and prolonged biological activities. , 1995, Journal of Medicinal Chemistry.

[131]  G. Barsh,et al.  Transgenic Expression of Syndecan-1 Uncovers a Physiological Control of Feeding Behavior by Syndecan-3 , 2001, Cell.

[132]  D. I. Våge,et al.  A ligand-mimetic model for constitutive activation of the melanocortin-1 receptor. , 1998, Molecular endocrinology.

[133]  C. Pouton,et al.  Influence of α-MSH terminal amino acids on binding affinity and biological activity in melanoma cells , 1994, Peptides.

[134]  K. Clément,et al.  Melanocortin-4 receptor mutations are a frequent and heterogeneous cause of morbid obesity. , 2000, The Journal of clinical investigation.

[135]  V. Hruby,et al.  Biological and conformational examination of stereochemical modifications using the template melanotropin peptide, Ac-Nle-c[Asp-His-Phe-Arg-Trp-Ala-Lys]-NH2, on human melanocortin receptors. , 1997, Journal of medicinal chemistry.

[136]  S. Huh,et al.  Solution structures of the melanocyte-stimulating hormones by two-dimensional NMR spectroscopy and dynamical simulated-annealing calculations. , 1998, European journal of biochemistry.

[137]  A. Grüters,et al.  Severe early-onset obesity, adrenal insufficiency and red hair pigmentation caused by POMC mutations in humans , 1998, Nature Genetics.

[138]  J. Rees,et al.  Melanocortin 1 receptor: what's red got to do with it? , 2001, Journal of the American Academy of Dermatology.

[139]  V. Hruby,et al.  Potent and prolonged acting cyclic lactam analogues of alpha-melanotropin: design based on molecular dynamics. , 1989, Journal of medicinal chemistry.

[140]  Shosuke Ito,et al.  Human melanocortin 1 receptor variants, receptor function and melanocyte response to UV radiation. , 2002, Journal of cell science.

[141]  V. Hruby,et al.  Design of potent linear α-melanotropin 4-10 analogues modified in positions 5 and 10 , 1989 .

[142]  J. Thornton,et al.  Analysis and prediction of the different types of β-turn in proteins , 1988 .

[143]  Y. Wan,et al.  Structure activity studies of the melanocortin-4 receptor by in vitro mutagenesis: identification of agouti-related protein (AGRP), melanocortin agonist and synthetic peptide antagonist interaction determinants. , 2001, Biochemistry.

[144]  R. Cone,et al.  Cyclic lactam alpha-melanotropin analogues of Ac-Nle4-cyclo[Asp5, D-Phe7,Lys10] alpha-melanocyte-stimulating hormone-(4-10)-NH2 with bulky aromatic amino acids at position 7 show high antagonist potency and selectivity at specific melanocortin receptors. , 1995, Journal of medicinal chemistry.

[145]  A. Thody,et al.  Melanocyte Function and Its Control by Melanocortin Peptides , 2002, The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society.

[146]  J. Shutter,et al.  Overexpression of Agrt leads to obesity in transgenic mice , 1997, Nature Genetics.

[147]  M. Tota,et al.  Molecular determinants of ligand binding to the human melanocortin-4 receptor. , 2000, Biochemistry.

[148]  D. Sargent,et al.  Preferred conformation, orientation, and accumulation of dynorphin A-(1-13)-tridecapeptide on the surface of neutral lipid membranes. , 1985, Biochemistry.

[149]  Stanley J. Watson,et al.  A biochemical function for attractin in agouti-induced pigmentation and obesity , 2001, Nature Genetics.

[150]  L. Sandkuijl,et al.  Melanocortin-1 receptor variant R151C modifies melanoma risk in Dutch families with melanoma. , 2001, American journal of human genetics.

[151]  Paolo Grieco,et al.  Novel cyclic templates of alpha-MSH give highly selective and potent antagonists/agonists for human melanocortin-3/4 receptors. , 2002, Journal of medicinal chemistry.

[152]  C. Haskell-Luevano,et al.  Characterization of aliphatic, cyclic, and aromatic N-terminally "capped" His-D-Phe-Arg-Trp-NH2 tetrapeptides at the melanocortin receptors. , 2003, European journal of pharmacology.

[153]  M. Parmentier,et al.  Molecular cloning of a mouse melanocortin 5 receptor gene widely expressed in peripheral tissues. , 1994, Biochemistry.

[154]  G. Rose,et al.  Turns in peptides and proteins. , 1985, Advances in protein chemistry.

[155]  L. Akkermans,et al.  Effects of Intraduodenal Bile on Interdigestive Gastrointestinal and Gallbladder Motility in Healthy Subjects , 2001, Digestion.

[156]  J. Wikberg,et al.  Molecular cloning and expression of the human melanocyte stimulating hormone receptor cDNA , 1992, FEBS letters.

[157]  M. Low,et al.  Receptors for the melanocortin peptides in the central nervous system , 1994 .

[158]  Christopher P Austin,et al.  A role for the melanocortin 4 receptor in sexual function , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[159]  C. Pouton,et al.  Synthesis and biological evaluation of α-MSH analogues substituted with alanine , 1994, Peptides.

[160]  T. Reisine,et al.  Main chain and side chain chiral methylated somatostatin analogs : syntheses and conformational analyses , 1992 .

[161]  Potent and selective peptide agonists of alpha-melanotropin action at human melanocortin receptor 4: their synthesis and biological evaluation in vitro. , 2001, Biochemical and biophysical research communications.

[162]  Zhimin Xiang,et al.  Structure-activity relationships of the melanocortin tetrapeptide Ac-His-DPhe-Arg-Trp-NH(2) at the mouse melanocortin receptors. 1. Modifications at the His position. , 2002, Journal of medicinal chemistry.